BRD4-targeted therapy ABBV-744 clinical data No Further a Mystery
In Section C, contributors will get ABBV-744 and oral navitoclax. In Section D, participants will get ABBV-744 and ruxolitinib. Contributors will receive treatment until eventually ailment progression or even the members are not able to tolerate the study drugs.Celastrol was recognized for a Myb inhibitor that suppressed C/EBPβ exercise and repres